Theralase® Provides Update on Bladder Cancer Clinical Study

posted Oct 08, 2024 9:00am  by  Theralase Technologies Inc.
"This latest update on our bladder cancer clinical study continues to strengthen our understanding of the potency of Ruvidar™ in the destruction of bladder cancer. It is a very effective drug and when activated by laser light, even more effective, providing both high efficacy and a high safety profile for patients. As Theralase® completes enrollment in its clinical study, this year and into the beginning of next year, Theralase® is actively seeking partnering / licensing opportunities.." ...read more